
The AACR-Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine represents a joint effort to encourage and support postdoctoral or clinical research fellows to conduct highly novel and provocative research in the field of regenerative cancer medicine and to establish a successful career path in this field. The research proposed for funding may be translational, clinical, or epidemiological in nature and must have direct applicability and relevance to enhancing the physiology or function of cancer survivors using regenerative medicine techniques.
The Immuno-Oncology 360° Summit reports on the rapid advancements of clinical, scientific and business developments of IO in one setting for a wider range of cancers at an accelerated rate. Now in its 5th year, IO360° is a strategic-level meeting for decision-makers. The three-day event features 10 plenary sessions with over 80 speakers and includes more than ten hours of networking. There will be over 450 attendees representing pharma, biotechs, academia, research organizations, and the investment community concentrating on IO.
In a disruptive, cutting-edge industry like ours, no single person or entity has all of the answers. By bringing together a diverse range of expertise from across the advanced therapies ecosystem, Phacilitate is creating a network of partnerships and relationships that bring us closer to achieving the ultimate goal of improving patient care and developing commercially viable curative treatments.
We bring people together through award-winning events, which focus on the business and the science of advanced therapies. Phacilitate Leaders World and Phacilitate Leaders Europe are the pillars of our calendar and bring together the entire advanced therapies ecosystem.
Bioregate Forum is a biennial European meeting dedicated to the “4R Medicine”: Repair, Replacement, Regeneration & Reprogramming. It will highlight the latest scientific, technological, clinical and commercialization approaches in the field of cell and gene therapy, stem cells, biomaterials and tissue engineering.
The race towards commercialisation of cell and gene products has already begun. Where technology innovations are pathing the way towards the development of these products, challenges surrounding scale up and closed system processing highlight areas that need our focus so that cell and gene therapy products can be produced on an industrial scale.
The Cell and Gene Therapy Manufacturing Forum is the only conference that is 100% dedicated to focusing on development of manufacturing processes for these products. With presentations on improving cost efficiency, innovative strategies for commercialisation as well as closed system processing, optimised manufacturing scheduling and maintaining GMP compliance, this forum is one that is not to be missed!
This comprehensive two-day summit, featuring over 40 presentations will provide experts with an exceptional environment in which to debate the key issues facing them today. The topics covered are Soft Tissue Engineering & Regenerative Medicine, Biomaterials & Bio Fabrication – Platforms & Technologies, Hard Tissue & Cartilage Engineering and Organ Fabrication & Bioprinting.
Two extended panel discussions will explore “engineering of viable tissue constructs and the challenges of vascularization” and “advances in 3D bioprinting techniques and challenges to be overcome”.
Join us in London on 12 & 13 November 2018.
The inaugural Breakthrough Symposium will bring the best minds in biotech together in the unlikely biotech hot spot of Fargo, N.D., to share knowledge, collaborate and discuss advances in gene and cell therapy and gene editing. The two-day event features a full agenda of scientific presentations, poster sessions and networking opportunities with thought leaders and innovators in the fast-growing areas of gene and cell therapy and gene editing. For more information and to register, visit breakthroughsymposium.com/.
The 24th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,000 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward.